Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Second Quarter 2013 Financial Results

  Opexa Therapeutics Announces News Release and Conference Call Schedule to
  Discuss Second Quarter 2013 Financial Results

Business Wire

THE WOODLANDS, Texas -- August 13, 2013

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing
Tcelna^®, a patient-specific T-cell immunotherapy for the treatment of
multiple sclerosis (MS), today announced that the company will report
financial results for the three months ended June 30, 2013, before the opening
of trading on Wednesday, August 14^th. The company will also conduct a
conference call and webcast to discuss financial results and provide a
corporate update at 8 A.M. Eastern Time on Wednesday, August 14^th.

Conference Call and Webcast Details

To listen to the conference call, dial in approximately ten minutes before the
scheduled 8 AM time to (253) 237-1170 or toll free at (877) 372-0867. Please
reference conference ID #31008302 while dialing into the call.

A live webcast of the call can also be accessed via the webcast link on our
website (www.opexatherapeutics.com) or by going to the following URL:

http://investor.shareholder.com/media/eventdetail.cfm?eventid=133472&CompanyID=OPXA&e=1&mediaKey=52AF10A2390CE08BC8D2847172A3B20C

There will be a brief Question & Answer session following management
commentary. Shareholders and interested parties are highly encouraged to
submit questions in advance by e-mail addressed to
kradhakrishnan@opexatherapeutics.com.

About Opexa

Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning
the interests of patients, employees and shareholders. The Company’s leading
therapy candidate, Tcelna^®, is a personalized T-cell immunotherapy that is in
a Phase IIb clinical development program (the Abili-T trial) for the treatment
of Secondary Progressive Multiple Sclerosis. Tcelna is derived from T-cells
isolated from the patient’s peripheral blood, expanded ex vivo, and
reintroduced into the patients via subcutaneous injections. This process
triggers a potent immune response against specific subsets of autoreactive
T-cells known to attack myelin.

About Multiple Sclerosis (MS)

Multiple Sclerosis is a chronic, inflammatory condition of the central nervous
system and is the most common, non-traumatic, disabling neurological disease
in young adults. It is estimated that approximately two million people have MS
worldwide.

While symptoms can vary, the most common symptoms of MS include blurred
vision, numbness or tingling in the limbs and problems with strength and
coordination. The relapsing forms of MS are the most common. The Secondary
Progressive form of MS represents about a third of the MS patient population.

For more information visit the Opexa Therapeutics website at
www.opexatherapeutics.com

About Tcelna

Tcelna is a potential personalized therapy that is under development to be
specifically tailored to each patient's disease profile. Tcelna is
manufactured using ImmPath™, Opexa's proprietary method for the production of
a patient-specific T-cell immunotherapy, which encompasses the collection of
blood from the MS patient, isolation of peripheral blood mononuclear cells,
generation of an autologous pool of myelin-reactive T-cells (MRTCs) raised
against selected peptides from myelin basic protein (MBP), myelin
oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP), and the
return of these expanded, irradiated T-cells back to the patient. These
attenuated T-cells are reintroduced into the patient via subcutaneous
injection to trigger a therapeutic immune system response.

Opexa is currently conducting a Phase IIb study of Tcelna. Named “Abili-T,”
the trial is a randomized, double-blind, placebo-controlled clinical study in
patients who demonstrate evidence of disease progression with or without
associated relapses. The trial is expected to enroll 180 patients at
approximately 30 leading clinical sites in the U.S. and Canada with each
patient receiving two annual courses of Tcelna treatment consisting of five
subcutaneous injections per year. The trial’s primary efficacy outcome is the
percentage of brain volume change (atrophy) at 24 months. Study investigators
will also measure several important secondary outcomes commonly associated
with MS, including disease progression as measured by the Expanded Disability
Status Scale (EDSS), annualized relapse rate and changes in disability as
measured by EDSS and the MS Functional Composite.

Contact:

Company
Karthik Radhakrishnan
Opexa Therapeutics, Inc.
Chief Financial Officer
281-775-0600
kradhakrishnan@opexatherapeutics.com
or
Investor Relations
Adam Cutler
The Trout Group
Adam Cutler
646-378-2936
opexa@troutgroup.com
 
Press spacebar to pause and continue. Press esc to stop.